- Home
- ANGH vs TLPH Comparison
ANGH vs TLPH Comparison
Compare ANGH & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | TLPH |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United Arab Emirates | United States |
| Employees | 186 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 37.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ANGH | TLPH |
|---|---|---|
| Price | $3.18 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8K | ★ 126.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.38 |
| 52 Week High | $7.05 | $1.57 |
Technical Indicators
Market Signals| Indicator | ANGH | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 57.94 |
| Support Level | $2.83 | $0.73 |
| Resistance Level | $4.00 | $1.02 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 47.34 | 62.16 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.